UBS Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-678
| Closed | -$447 | – | 10413 |
|
|
2024
Q2 | $447 | Hold |
678
| – | – | ﹤0.01% | 8919 |
|
|
2024
Q1 | $409 | Sell |
678
-1
| -0.1% | -$1 | ﹤0.01% | 8582 |
|
|
2023
Q4 | $399 | Sell |
679
-13,567
| -95% | -$8.16K | ﹤0.01% | 8684 |
|
|
2023
Q3 | $9.49K | Buy |
14,246
+7,455
| +110% | +$9.13K | ﹤0.01% | 7136 |
|
|
2023
Q2 | $22.3K | Buy |
6,791
+2,949
| +77% | +$8.91K | ﹤0.01% | 6822 |
|
|
2023
Q1 | $34.9K | Sell |
3,842
-354
| -8% | -$5.01K | ﹤0.01% | 6695 |
|
|
2022
Q4 | $49.1K | Buy |
4,196
+4,084
| +3,646% | +$72K | ﹤0.01% | 6803 |
|
|
2022
Q3 | $2K | Hold |
112
| – | – | ﹤0.01% | 9819 |
|
|
2022
Q2 | $3K | Sell |
112
-34,291
| -100% | -$1.17M | ﹤0.01% | 9398 |
|
|
2022
Q1 | $1.71M | Buy |
34,403
+10,765
| +46% | +$532K | ﹤0.01% | 3585 |
|
|
2021
Q4 | $1.66M | Buy |
23,638
+8,298
| +54% | +$699K | ﹤0.01% | 3909 |
|
|
2021
Q3 | $1.43M | Buy |
15,340
+13,430
| +703% | +$1.28M | ﹤0.01% | 3878 |
|
|
2021
Q2 | $192K | Sell |
1,910
-16,109
| -89% | -$1.57M | ﹤0.01% | 5381 |
|
|
2021
Q1 | $1.68M | Buy |
+18,019
| New | +$1.83M | ﹤0.01% | 3747 |
|
|
2020
Q4 | – | Sell |
-33
| Closed | -$3K | – | 8866 |
|
|
2020
Q3 | $3K | Sell |
33
-2,503
| -99% | -$292K | ﹤0.01% | 7577 |
|
|
2020
Q2 | $236K | Sell |
2,536
-871
| -26% | -$48K | ﹤0.01% | 4683 |
|
|
2020
Q1 | $97K | Sell |
3,407
-4,530
| -57% | -$176K | ﹤0.01% | 5324 |
|
|
2019
Q4 | $329K | Buy |
7,937
+2,569
| +48% | +$56.3K | ﹤0.01% | 5210 |
|
|
2019
Q3 | $76K | Buy |
5,368
+5,061
| +1,649% | +$106K | ﹤0.01% | 5936 |
|
|
2019
Q2 | $11K | Buy |
+307
| New | +$16.6K | ﹤0.01% | 7037 |
|
|
2018
Q4 | – | Sell |
-66
| Closed | -$5K | – | 8376 |
|
|
2018
Q3 | $5K | Buy |
66
+53
| +408% | +$3.5K | ﹤0.01% | 7517 |
|
|
2018
Q2 | $1K | Buy |
+13
| New | +$1.26K | ﹤0.01% | 7854 |
|
|
2018
Q1 | – | Sell |
-57
| Closed | -$7K | – | 8245 |
|
|
2017
Q4 | $7K | Buy |
57
+32
| +128% | +$3.93K | ﹤0.01% | 7251 |
|
|
2017
Q3 | $3K | Sell |
25
-234
| -90% | -$28.1K | ﹤0.01% | 7412 |
|
|
2017
Q2 | $34K | Buy |
+259
| New | +$34.9K | ﹤0.01% | 5937 |
|
|
2017
Q1 | – | Sell |
-94
| Closed | -$9K | – | 8066 |
|
|
2016
Q4 | $9K | Buy |
+94
| New | +$8.97K | ﹤0.01% | 6991 |
|
|
2016
Q3 | – | Sell |
-76
| Closed | -$9K | – | 7996 |
|
|
2016
Q2 | $9K | Buy |
+76
| New | +$7.61K | ﹤0.01% | 6852 |
|
|
2016
Q1 | – | Sell |
-131
| Closed | -$10K | – | 8307 |
|
|
2015
Q4 | $10K | Buy |
131
+125
| +2,083% | +$9.56K | ﹤0.01% | 7294 |
|
|
2015
Q3 | $0 | Sell |
6
-52
| -90% | -$4.12K | ﹤0.01% | 8700 |
|
|
2015
Q2 | $5K | Buy |
58
+33
| +132% | +$2.7K | ﹤0.01% | 7891 |
|
|
2015
Q1 | $2K | Buy |
25
+13
| +108% | +$1.16K | ﹤0.01% | 8468 |
|
|
2014
Q4 | $1K | Buy |
+12
| New | +$947 | ﹤0.01% | 9565 |
|
UBS Group's VBIV Position: Q3 2024 in Review
UBS Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 678 shares — an estimated $447 sold.
UBS Group first reported a position in VBIV in Q4 2014 and held it in 32 quarters. The position peaked at $1.71M in Q1 2022. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.
- UBS Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 678 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $447.
- UBS Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2014 and held it in 32 quarters.
- UBS Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $1.71M in Q1 2022.
- 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.